RESULTS OF TREATMENT WITH RECOMBINANT HUMAN GROWTH HORMONE WITHOUT METHIONINE |[lpar]|r-hGH|[rpar]| IN PATIENTS |[lpar]|PTS|[rpar]| WITH GROWTH HORMONE DEFICIENCY |[lpar]|GHD|[rpar]|

摘要

255 pts with GHD (180 boys, 75 girls, age 0.5-19.9(11.1+/-3.7), bone age 0-17(8.9+/-3.5)yrs, height SDS for chronologic age -2.8 +/-1.0) are currently treated with r-hGH sc(12.6+/-1.81U and 5.8 +/-1.3 injections/week).By mid-april, 181 pts had been treated for 3, 89 for 6, 27 for 9, and 11 for 12 months. 122 had isolated GHD, the others additional defects with adequate replacement(including 29 craniopharyngeomas, 19 other organic causes and irradiation). 93 had been transferred from pit- or met-hGH. Routine blood analyses were normal before and on treatment. With exception of mild local burning, no side-effects were noted. Mean height velocities (cm/yr, 3 month periods, SEM 0.2-0.9) were:IGF1 increased from 14(6-26) to 25(12-47)nmol/l(6m, without transfer**). hGH antibodies were found in 2 new (3-9 months) and 14 transfer pts(before r-hGH). E.coli protein antibodies did not increase. It is concluded that r-hGH is effective and safe in GHD.